Publications by authors named "M G Reale"

The indiscriminate use of plastic products and their inappropriate management and disposal contribute to the increasing presence and accumulation of this material in all environmental zones. The chemical properties of plastics and their resistance to natural degradation lead over time to the production of microplastics (MPs) and nanoplastics, which are dispersed in soil, water, and air and can be absorbed by plants, including those grown for food. In agriculture, MPs can come from many sources (mulch film, tractor tires, compost, fertilizers, and pesticides).

View Article and Find Full Text PDF

Introduction: The advocacy Women Against Lung Cancer in Europe (WALCE) promoted the European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA) and provided a free-of-charge molecular profiling platform for NSCLC sample characterization with the aim of increasing the detection of targetable drivers and improving patients' access to clinical trials in Europe.

Methods: From January 2021 to December 2023, 20 centers located at five different European countries (Greece, Slovenia, Romania, Albania, and Italy) joined EPROPA, with 555 patients with advanced NSCLC registered to the program. Anonymized patients' clinical-pathological data were shared through the EPROPA web platform and tissue samples were collected at the Molecular Pathology Unit of the Reference Center (University of Turin) for molecular analyses.

View Article and Find Full Text PDF
Article Synopsis
  • The MET exon 14 skipping mutation is a rare occurrence in non-small-cell lung cancer (NSCLC), found in 3%-4% of cases, and this study analyzes the characteristics and treatment outcomes for patients from the Italian ATLAS registry.
  • In a cohort of 146 advanced METex14 NSCLC patients, treated primarily with MET inhibitors capmatinib (38%) and tepotinib (23%), the response rate was 37% and the disease control rate was 62%, with median progression-free survival of 6.6 months and overall survival of 10.7 months.
  • Adverse effects were noted in 12% of patients, with serious complications requiring dose modifications in a small percentage, indicating
View Article and Find Full Text PDF

In gastrointestinal (GI) diseases, lipopolysaccharide (LPS) exacerbates gut-barrier dysfunction and inflammation. Cinnamoyl derivatives show potential in mitigating LPS-induced inflammation. We assessed intestinal epithelial barrier function using -epithelial electrical resistance values and measured inflammatory mediators through real-time PCR and ELISA in Caco-2 cells.

View Article and Find Full Text PDF